Genome-Wide Meta-Analysis of Quantitatively Measured Generalized Anxiety Symptoms in Individuals of European Ancestry

Why It Matters

The findings demonstrate that quantitative anxiety measures capture a substantial and distinct genetic architecture, expanding potential therapeutic targets and enabling more precise risk prediction across diverse populations.

Key Takeaways

• 80 genome-wide significant SNPs found across 74 loci in 693k Europeans
• 39 loci are novel for anxiety, 16 never linked to internalizing traits
• Top hits near RP4-598G3.1 lncRNA and PCLO gene
• SNP heritability of GAD symptoms estimated at 5.9%
• Polygenic scores predict anxiety risk across European, African, South Asian ancestries

Pulse Analysis

Anxiety disorders affect roughly one in three adults worldwide and are rising in prevalence, creating a pressing need for deeper biological insight. While twin studies have long suggested a moderate genetic component, early case‑control GWAS struggled to pinpoint robust loci because they focused on binary diagnoses. By leveraging quantitative symptom scores from the GAD‑7 scale, researchers can capture the full continuum of anxiety severity, boosting statistical power and revealing genetic influences that operate below clinical thresholds.

The new meta‑analysis, encompassing nearly 700,000 European‑ancestry participants, identified 80 independent genome‑wide significant variants across 74 loci. Notably, 39 of these loci have not been reported in prior anxiety GWAS, and 16 are completely novel to internalizing traits, underscoring previously hidden biology. The top associations near RP4‑598G3.1 and within PCLO echo earlier links to neuropsychiatric phenotypes and point to pathways such as GABAergic signaling and synaptic function. SNP‑based heritability of 5.9% aligns with expectations for complex traits and confirms that common variants contribute meaningfully to anxiety symptom variance.

Beyond discovery, the study evaluated polygenic risk scores in independent cohorts of European, African and South Asian ancestry, demonstrating modest but consistent predictive performance across groups. This cross‑population portability suggests that the identified genetic architecture is broadly relevant and may inform future precision‑medicine approaches, from risk stratification to drug target validation. As larger biobanks and more diverse samples become available, expanding these analyses will refine our understanding of anxiety’s genetic underpinnings and accelerate the translation of genomic insights into clinical practice.